Lantus sales are dropping fast because of the ... on the FDA’s finding of safety and effectiveness for Humalog (insulin lispro injection) to support approval, but also provided Admelog-specific ...
The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart) and Eli Lilly's Humalog (insulin lispro) – will be priced at no ...
Express Scripts reported that the price of Lantus and Humalog rose 22.7% and 19.9%, respectively, from 2014 to 2015. In 2014, Sanofi got $6.93 billion in revenue from Lantus. Steve Miller, chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback